Prevalence of SARS-CoV-2 Antibodies in Kosovo-Wide Population-Based Seroepidemiological Study.
COVID‐19
Kosovo
SARS‐CoV‐2
antibodies
seroepidemiological study
seroprevalence
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
revised:
28
07
2024
received:
06
02
2024
accepted:
16
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
3
9
2024
Statut:
ppublish
Résumé
Seroprevalence studies have proven to be an important tool in tracking the progression of the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to measure the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the general population of Kosovo by gender, age group and region and among asymptomatic people. The Institute of Public Health of Kosovo conducted a cross-sectional population-based survey, aligned with the protocols of the WHO Unity Studies, from the beginning of May to the end of June 2021. The survey covered a total of 2204 people with a response rate of 91.8% (41.9% [923] males and 51.2% [1281] females). In May to June 2021, the prevalence of antibodies in the overall population (IgG antibodies ≥ 1.1) was 37.0%. Seroprevalence was 34.4% in men and 38.9% in women (p < 0.05), with the highest percentage (48.7%) found in the 60-69 years' age group. The overall prevalence of acute IgM antibodies (IgM ≥ 1.1) was 1% (95% CI: 0.7%-1.5%), with no significant difference between genders and the highest prevalence among participants of 60-69 years of age (1.6%; 95% CI: 0.7%-3.6%). A high prevalence of antibodies against SARS-CoV-2 was found in Kosovo before the start of the vaccination campaign. However, the results of the survey suggested that, by the end of June 2021, a desirable level of protection from the SARS-CoV-2 virus had not been reached.
Sections du résumé
BACKGROUND
BACKGROUND
Seroprevalence studies have proven to be an important tool in tracking the progression of the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to measure the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the general population of Kosovo by gender, age group and region and among asymptomatic people.
METHOD
METHODS
The Institute of Public Health of Kosovo conducted a cross-sectional population-based survey, aligned with the protocols of the WHO Unity Studies, from the beginning of May to the end of June 2021.
RESULTS
RESULTS
The survey covered a total of 2204 people with a response rate of 91.8% (41.9% [923] males and 51.2% [1281] females). In May to June 2021, the prevalence of antibodies in the overall population (IgG antibodies ≥ 1.1) was 37.0%. Seroprevalence was 34.4% in men and 38.9% in women (p < 0.05), with the highest percentage (48.7%) found in the 60-69 years' age group. The overall prevalence of acute IgM antibodies (IgM ≥ 1.1) was 1% (95% CI: 0.7%-1.5%), with no significant difference between genders and the highest prevalence among participants of 60-69 years of age (1.6%; 95% CI: 0.7%-3.6%).
CONCLUSION
CONCLUSIONS
A high prevalence of antibodies against SARS-CoV-2 was found in Kosovo before the start of the vaccination campaign. However, the results of the survey suggested that, by the end of June 2021, a desirable level of protection from the SARS-CoV-2 virus had not been reached.
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70004Subventions
Organisme : WHO
Informations de copyright
© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
C. Huang, Y. Wang, X. Li, et al., “Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China,” Lancet 395, no. 10223 (2020): 497–506, https://doi.org/10.1016/S0140‐6736(20)30183‐5.
N. Zhu, D. Zhang, W. Wang, et al., “A Novel Coronavirus From Patients With Pneumonia in China, 2019,” New England Journal of Medicine 382 (2020): 727–733, https://doi.org/10.1056/NEJMoa2001017.
“WHO Statement on Novel Coronavirus in Thailand,” in News release, World Health Organization [Website], January 13, 2020 (Geneva: World Health Organization, 2023), accessed October 18, 2023, https://www.who.int/news/item/13‐01‐2020‐who‐statement‐on‐novel‐coronavirus‐in‐thailand.
“WHO Director‐General's Opening Remarks at the Media Briefing on COVID‐19,” World Health Organization [Website], March 11, 2020 (Geneva: World Health Organization, 2023), accessed October 18, 2023, https://www.who.int/director‐general/speeches/detail/who‐director‐general‐s‐opening‐remarks‐at‐the‐media‐briefing‐on‐covid‐19‐‐‐11‐march‐2020.
“WHO Coronavirus Disease (COVID‐19) Dashboard [Database]” (Geneva: World Health Organization, 2023), accessed October 18, 2023, https://covid19.who.int/.
“Kosova në shifra 2021 Kosovo in Code 2021” (Prishtina: Kosovo Agency of Statistics, 2022).
G. Bojaj, R. Agahi, and I. Hoxha, “Treatment of the First COVID‐19 Case in Kosovo and Management of the Pandemic,” Science Progress Research 1, no. 3 (2021): 250–254.
“COVID‐19 Data From the Institute of Public Health as of 8th May 2022,” Institute of Public Health of Kosovo.
“Nis vaksinimi masiv, MSH‐ja thotë se ka doza të mjaftueshme. 15 Gershor 2021 [Mass Vaccination Starting, the Ministry of Health Says There Are Enough Doses 15 January 2021],” in Radio Evropa e Lirë – Lajmet [Radio Free Europe – News] [Website] (Prague: Radio Free Europe, 2023), accessed October 18, 2023, https://www.evropaelire.org/a/vaksinimi‐masiv‐ne‐kosove‐/31308445.html.
“Të martën pritet të nis vaksinimi masiv në Kosovë, ndërkohë në dispozicion janë vetëm 97 mijë vaksina [Mass vaccination is Expected to Start in Kosovo on Tuesday, While Only 97,000 Vaccines Are Available]”, in telegrafi [website] (Pristina: Telegrafi sh.p.k., 2022), accessed October 18, 2023, https://telegrafi.com/te‐marten‐pritet‐te‐nis‐vaksinimi‐masiv‐ne‐kosove‐nderkohe‐ne‐dispozicion‐jane‐vetem‐97‐mije‐vaksina/.
N. Bobrovitz, R. K. Arora, C. Cao, et al., “Global Seroprevalence of SARS‐CoV‐2 Antibodies: A Systematic Review and Meta‐Analysis,” PLoS ONE 16, no. 6 (2021): e0252617, https://doi.org/10.1371/journal.pone.0252617.
G. Sulcebe, A. Ylli, F. Cenko, and M. Kurti‐Prifti, “Rapid Increase of SARS‐CoV‐2 Seroprevalence During the 2020 Pandemic Year in the Population of the City of Tirana, Albania,” Heliyon 9, no. 9 (2023): e19547, https://doi.org/10.1016/j.heliyon.2023.e19547.
T. Vilibic‐Cavlek, V. Stevanovic, M. Ilic, et al., “SARS‐CoV‐2 Seroprevalence and Neutralizing Antibody Response After the First and Second COVID‐19 Pandemic Wave in Croatia,” Pathogens 10, no. 6 (2021): 774, https://doi.org/10.3390/pathogens10060774.
“Population‐Based Age‐Stratified Seroepidemiological Investigation Protocol for COVID‐19 Virus Infection” (Geneva: World Health Organization, 2020), accessed October 18, 2023, https://www.who.int/publications/i/item/WHO‐2019‐nCoV‐Seroepidemiology‐2020.2.
H. Cerutti, T. Bandini, M. Castria, et al., “A Quantitative Assay for Detection of SARS‐CoV‐2 Neutralizing Antibodies,” Journal of Clinical Virology 147 (2022): 105064, https://doi.org/10.1016/j.jcv.2021.105064.
G. Sulcebe, A. Ylli, F. Cenko, et al., “Trends in SARS‐CoV‐2 Seroprevalence in Albania During the 2021–2022 Pandemic Year,” New Microbes and New Infections 56 (2024): 101208.
L. Ya'qoub, I. Y. Elgendy, and C. J. Pepine, “Sex and Gender Differences in COVID‐19: More to Be Learned!” American Heart Journal Plus: Cardiology Research and Practice 3 (2021): 100011.
I. Bergeri, M. G. Whelan, H. Ware, et al., “Global SARS‐CoV‐2 Seroprevalence From January 2020 to April 2022: A Systematic Review and Meta‐Analysis of Standardized Population‐Based Studies,” PLoS Medicine 19, no. 11 (2022): e1004107, https://doi.org/10.1371/journal.pmed.1004107.
A. Barchuk, D. Skougarevskiy, A. Kouprianov, et al., “COVID‐19 Pandemic in Saint Petersburg, Russia: Combining Surveillance and Population‐Based Serological Study Data,” PLoS ONE 17, no. 6 (2022): e0266945, https://doi.org/10.1371/journal.pone.0266945.
S. Bellizzi, L. Alsawalha, S. S. Ali, et al., “A Three‐Phase Population Based Sero‐Epidemiological Study: Assessing the Trend in Prevalence of SARS‐CoV‐2 During COVID‐19 Pandemic in Jordan,” One Health 13 (2021): 100292, https://doi.org/10.1016/j.onehlt.2021.100292.
R. K. Arora, A. Joseph, J. Van Wyk, et al., “SeroTracker: A Global SARS‐CoV‐2 Seroprevalence Dashboard,” Lancet Infectious Diseases 21, no. 4 (2021): e75–e76, https://doi.org/10.1016/S1473‐3099(20)30631‐9.
A. Garcia‐Agundez, O. Ojo, H. A. Hernández‐Roig, et al., “Estimating the COVID‐19 Prevalence in Spain With Indirect Reporting via Open Surveys,” Frontiers in Public Health 9 (2021): 658544, https://doi.org/10.3389/fpubh.2021.658544.
L. Espenhain, S. Tribler, C. Sværke Jørgensen, C. Holm Hansen, U. Wolff Sönksen, and S. Ethelberg, “Prevalence of SARS‐CoV‐2 Antibodies in Denmark: Nationwide, Population‐Based Seroepidemiological Study,” European Journal of Epidemiology 36, no. 7 (2021): 715–725, https://doi.org/10.1007/s10654‐021‐00796‐8.
E. Bendavid, B. Mulaney, N. Sood, et al., “Covid‐19 Antibody Seroprevalence in Santa Clara County, California,” International Journal of Epidemiology 50, no. 2 (2021): 410–419, https://doi.org/10.1093/ije/dyab010.
M. F. Reyes‐Vega, M. G. Soto‐Cabezas, F. Cárdenas, et al., “SARS‐CoV‐2 Prevalence Associated to Low Socioeconomic Status and Overcrowding in an LMIC Megacity: A Population‐Based Seroepidemiological Survey in Lima, Peru,” EClinicalMedicine 34 (2021): 100801, https://doi.org/10.1016/j.eclinm.2021.100801.
P. Cerino, A. Coppola, P. Volzone, et al., “Seroprevalence of SARS‐CoV‐2‐Specific Antibodies in the Town of Ariano Irpino (Avellino, Campania, Italy): A Population‐Based Study,” Future Science OA 7, no. 4 (2021): FSO673, https://doi.org/10.2144/fsoa‐2020‐0203.
Z. Bogogiannidou, A. Vontas, K. Dadouli, et al., “Repeated Leftover Serosurvey of SARS‐CoV‐2 IgG Antibodies, Greece, March and April 2020,” Euro Surveillance 25, no. 31 (2020): 2001369, https://doi.org/10.2807/1560‐7917.ES.2020.25.31.2001369.
M. Ralli, A. Arcangeli, P. M. Soave, C. Voglino, and F. De‐Giorgio, “SARS‐CoV‐2 Seroprevalence in the Vatican City State,” European Journal of Internal Medicine 86 (2021): 98–99, https://doi.org/10.1016/j.ejim.2021.01.029.
S. Stringhini, A. Wisniak, G. Piumatti, et al., “Seroprevalence of Anti‐SARS‐CoV‐2 IgG Antibodies in Geneva, Switzerland (SEROCoV‐POP): A Population‐Based Study,” Lancet 396, no. 10247 (2020): 313–319, https://doi.org/10.1016/S0140‐6736(20)31304‐0.
N. A. Aziz, V. M. Corman, A. K. Echterhoff, et al., “Seroprevalence and Correlates of SARS‐CoV‐2 Neutralizing Antibodies From a Population‐Based Study in Bonn, Germany,” Nature Communications 12, no. 1 (2021): 2117, https://doi.org/10.1038/s41467‐021‐22,351‐5.
S. A. Herzog, J. De Bie, S. Abrams, et al., “Seroprevalence of IgG Antibodies Against SARS‐CoV‐2–A Serial Prospective Cross‐Sectional Nationwide Study of Residual Samples, Belgium, March to October 2020,” Euro Surveillance 27, no. 9 (2022): 2100419, https://doi.org/10.2807/1560‐7917.ES.2022.27.9.2100419.
R. Abdul‐Raheem, S. Moosa, F. Waheed, et al., “A Sero‐Epidemiological Study After Two Waves of the COVID‐19 Epidemic,” Asian Pacific Journal of Allergy and Immunology (2021), https://doi.org/10.12932/AP‐040721‐1177.